BENIGN PROSTATIC HYPERTROPHY: AMINO ACID THERAPY FOR SYMPTOMATIC RELIEF

1962 ◽  
Vol 10 (5) ◽  
pp. 426-430 ◽  
Author(s):  
FREDERIC DAMRAU
Keyword(s):  
Amino Acid ◽  
Symptomatic Relief ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Acid Therapy

Multicentre Controlled Trial of Indoramin in the Symptomatic Relief of Benign Prostatic Hypertrophy

1990 ◽  
Vol 65 (1) ◽  
pp. 36-38 ◽  
Author(s):  
W. CHOW ◽  
D. HAHN ◽  
D. SANDHU ◽  
P. SLANEY ◽  
R. HENSHAW ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Symptomatic Relief ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy

Laser treatment of benign prostatic hypertrophy

1996 ◽  
Vol 63 (1) ◽  
pp. 77-80
Author(s):  
S. Guazzieri ◽  
W. Cecchetti ◽  
M. Meneguolo ◽  
G. D'incà ◽  
R. Bertoldin
Keyword(s):  
Laser Treatment ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Laser Source ◽  
Experimental Procedure ◽  
The Usa ◽  
Side Emission ◽  
Pace Maker ◽  
Stable Laser ◽  
Good Flow

— Laser treatment of benign prostatic hypertrophy (BPH) has gradually become more widespread over the last few years. In the USA it is considered an alternative to endoscopic resection as far as insurance payments are concerned. Different methods are used but the most common and suitable one for urologists is the removal and coagulation of the prostatic tissue under visual control (VLAP or ELAP). The Authors report their personal experience in this type of treatment where good results are due to: 1) combination of a powerful, stable laser source 2) durable side-emission contact fibre 3) laser resector, which also in the absence of epicystostomy maintains a good flow during the operation. However, “laser resection” should still be considered an experimental procedure to be used for randomised protocols or on selected patients (high risk of bleeding, Jehovah's witnesses, carriers of pace-maker, etc.).

SECRETION OF DIHYDROTESTOSTERONE BY HUMAN PROSTATE IN BENIGN PROSTATIC HYPERTROPHY

1974 ◽  
Vol 77 (2) ◽  
pp. 401-407 ◽  
Author(s):  
J. A. Mahoudeau ◽  
A. Delassalle ◽  
H. Bricaire
Keyword(s):  
Plasma Levels ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Human Prostate ◽  
Control Subjects ◽  
Peripheral Plasma ◽  
Significant Difference ◽  
Before And After ◽  
The Mean ◽  
And Control

ABSTRACT Plasma levels of testosterone (T) and 5α-dihydrotestosterone (DHT) were determined by radioimmunoassay in 29 patients with benign prostatic hypertrophy (BPH) and in 56 control men of various ages. No significant difference was found in T, DHT nor DHT/T ratio between BPH and control subjects of similar age. Plasma DHT was higher in the prostatic than in the peripheral veins in 8/9 patients with BPH during laparotomy, indicating a prostatic secretion of DHT. No difference in the mean T nor the mean DHT was found in peripheral plasma before and after adenomectomy.

Urogastrone–epidermal growth factor concentrations in prostatic fluid of normal individuals and patients with benign prostatic hypertrophy

1986 ◽  
Vol 70 (4) ◽  
pp. 359-363 ◽  
Author(s):  
H. Gregory ◽  
I. R. Willshire ◽  
J. P. Kavanagh ◽  
N. J. Blacklock ◽  
S. Chowdury ◽  
...  
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Seminal Fluid ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Prostatic Fluid ◽  
Show Evidence ◽  
Epidermal Growth ◽  
High Concentrations ◽  
Normal Males

1. High concentrations (272 ± 33 ng/ml) of urogastrone-epidermal growth factor were measured in prostatic fluid from normal males by a specific radioimmunoassay. 2. Significantly lower concentrations (155 ± 24 ng/ml) were observed in the prostatic fluid of patients with benign prostatic hypertrophy than in the age-matched normal controls (2P < 0.01). 3. The growth factor content of seminal fluid was accounted for by the contribution of prostatic fluid. 4. Immunochemical studies failed to show evidence of synthesis within the gland nor could high affinity receptors for the protein be demonstrated in membrane preparations of the gland.

Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial

Homeopathy ◽  
2012 ◽  
Vol 101 (04) ◽  
pp. 217-223 ◽  
Author(s):  
A.K. Hati ◽  
B. Paital ◽  
K.N. Naik ◽  
A.K. Mishra ◽  
G.B.N. Chainy ◽  
...  
Keyword(s):  
Specific Antigen ◽  
Urine Volume ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Intermittent Flow ◽  
Urinary Flow ◽  
Residual Urine Volume ◽  
Homeopathic Treatment ◽  
Presenting Symptoms ◽  
Residual Urine

Background: Benign Prostatic Hypertrophy (BPH) is common in older men. This study compared homeopathic treatment strategies using constitutional medicines (CM) or organopathic medicines (OM) alone or in combination (BCOM) in patients suffering from BPH.Methods: 220 men aged 30–90 years were recruited in Odisha, India. Patients presenting symptoms of prostatism, with or without evidence of bladder outflow obstruction were included in the study. Patients with serum prostate specific antigen (PSA)> 4 nmol/mL, malignancy, complete urine retention, stone formation and gross bilateral hydronephrosis were excluded. Patients were sequentially allocated to OM, CM or BCOM. The main outcome measure was the International Prostate Symptom Score (IPSS).Results: 73, 70 and 77 patients respectively were sequentially allocated to OM, CM or BCOM. 180 patients (60 per group) completed treatment and were included in the final analysis. Overall 85% of patients showed improvement of subjective symptoms such as frequency, urgency, hesitancy, intermittent flow, unsatisfactory urination, feeble stream, diminution of residual urine volume but there was no reduction in prostate size. Treatment response was highest with BCOM (38.24%) compared to OM (31.62%) and CM (30.15%). Effect sizes were highest for the decrease in IPSS, residual urine volume and urinary flow rate.

Sign in / Sign up

Export Citation Format

Share Document